Kura Oncology’s (KURA) Market Outperform Rating Reiterated at JMP Securities

JMP Securities reissued their market outperform rating on shares of Kura Oncology (NASDAQ:KURA) in a report published on Tuesday,Benzinga reports. The firm currently has a $32.00 target price on the stock.

Other research analysts have also issued reports about the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research report on Wednesday, November 6th. StockNews.com raised shares of Kura Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday, November 12th. HC Wainwright reissued a “buy” rating and issued a $32.00 price objective on shares of Kura Oncology in a research report on Wednesday, November 13th. Stifel Nicolaus lowered shares of Kura Oncology from a “buy” rating to a “hold” rating and dropped their price objective for the company from $26.00 to $19.00 in a research note on Monday, October 14th. Finally, Lifesci Capital raised shares of Kura Oncology to a “strong-buy” rating in a research report on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $29.43.

Kura Oncology Trading Down 37.1 %

Shares of KURA stock opened at $10.00 on Tuesday. The company has a market capitalization of $777.68 million, a P/E ratio of -4.45 and a beta of 0.86. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The business’s 50 day moving average is $18.28 and its two-hundred day moving average is $19.82. Kura Oncology has a twelve month low of $9.06 and a twelve month high of $24.17.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of KURA. Suvretta Capital Management LLC increased its position in Kura Oncology by 8.2% in the 3rd quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock worth $149,535,000 after purchasing an additional 583,155 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Kura Oncology by 0.7% during the first quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock valued at $86,726,000 after buying an additional 28,212 shares during the last quarter. Avoro Capital Advisors LLC increased its position in shares of Kura Oncology by 29.2% during the first quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock valued at $82,120,000 after purchasing an additional 870,000 shares during the period. Armistice Capital LLC boosted its position in shares of Kura Oncology by 14.7% during the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after acquiring an additional 302,000 shares in the last quarter. Finally, Artal Group S.A. grew its stake in shares of Kura Oncology by 8.6% in the 1st quarter. Artal Group S.A. now owns 1,919,884 shares of the company’s stock valued at $40,951,000 after purchasing an additional 151,828 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.